malignant lymphoma
Conditions
Interventions
Synbiotics: Use of Gfine in patients who receive autologous PBSCT
Placebo: Use of Placebo in patients who receive autologous PBSCT
Sponsors
Department of Medicine, Kobe University Hospital and Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Malignant lymphoma who can be candidate for autologous PBSCT (2) 17<Age<66 (3) ECOG PS <2 (4) No obvious organ failure (5) They have given written informed consent (6) Patients who will survive more than 3 months
Exclusion criteria
Exclusion criteria: (1) History of stem cell transplantation (2) HIV carrier (3) Uncontrolled active infectious diseases (4) Pregnant or lactating (5) Uncontrolled psychological disorder (6) Allergy for the drugs used for the conditioning regimen (7) Allergy for Gfine (8) Patients who do not tolerate the maximal defined conditioning regimen due to organ dysfunction (e.g., reduce MCNU due to pulmonary dysfunction, reduce Carboplatin due to renal dysfunction) (9) Patients who do not ingest enough calories (10) Investigator rejection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of TPN | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Diarrhea and infectious diseases (2) Regimen related toxicity except diarrhea and infectious diseases (3) Engraftment (4) Effect of appetite hormone (5) Quality of life (6) GLP-2 blood level (7) Nutritional condition (8) Length of stay and Cost-effectiveness (9) Period of failure to TPN administer | — |
Countries
Japan
Contacts
Public ContactYu Mizutani
Kobe University Hospital Medical Oncology/Hematology
Outcome results
None listed